Clin2
NCT07333716Possibly a fitRecruiting

Desloratadine for mild to moderate UC

Ulcerative Colitis (UC)Ulcerative Colitis

Treatments studied

Part of Digestive system clinical trials.

This trial tests whether desloratadine, an allergy medicine (antihistamine), can help reduce inflammation in people with mild to moderate ulcerative colitis. All participants must already be taking mesalamine and cannot be on other stronger UC treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
44 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have mild or moderate ulcerative colitis (not severe).
  • You are currently taking mesalamine (a common UC medicine).
  • You are not using steroids, immunosuppressants, or biologics for your UC.
  • You have no allergy to desloratadine or similar antihistamine drugs.
  • You have no other inflammatory disease, history of colon cancer, or colon removal surgery.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07064707Recruiting· Phase 2
Rupatadine for mild to moderate ulcerative colitis

This study is testing if the allergy medicine rupatadine can help calm inflammation in people with mild to moderate ulcerative colitis. It is for people who are not already on strong UC treatments and want to try a new option.

Alexandria
NCT06067698Recruiting
Alpha lipoic acid for mild to moderate ulcerative colitis

This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.

Tanta
NCT06335160Recruiting
Mebendazole for mild to moderate ulcerative colitis

This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.

Tanta
NCT06993974Recruiting· Phase 2
Nitazoxanide for mild to moderate ulcerative colitis

This trial tests if a medication called nitazoxanide can help people with mild to moderate ulcerative colitis (UC). It may be a treatment option for those not already on strong UC medications.

Alexandria
NCT06420375Recruiting· Phase 2
New treatment for active ulcerative colitis

This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.

Chestnut Hill, Massachusetts
NCT06525974Not yet recruiting· Early Phase 1
Febuxostat for mild to moderate ulcerative colitis

This trial tests if adding febuxostat to your usual mesalamine treatment can help improve mild to moderate ulcerative colitis. It's for adults with confirmed UC who are not on steroids or other immune-suppressing drugs.

Hear when a new Ulcerative Colitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.